-
Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
•
Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum of understanding (MoU) with China Meheco International, a move that will facilitate the export of Daewoong’s pharmaceutical products into the Chinese market. This comprehensive agreement encompasses the entire portfolio of Daewoong’s products, including their innovative…
-
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
•
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has been filed in China for Fexuclu/Abcito (fexuprazan) in a 40mg dosage form. Fexuclu, an in-house developed potassium-competitive acid blocker (P-CAB), represents a new generation of therapies for gastroesophageal reflux disease (GERD). Advantages of P-CABs Over…
-
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
•
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have been released, detailing the volumes and provinces awarded for each tender. The round saw RMB 3.775 billion (USD 550 million) in bid spots distributed among a total of 152 manufacturers, resulting in over 252 valid…
-
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
•
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers…
